StopUMTS Logo
how to get rid of moles 
Zoeken
   
Voorlichting
16/08/18Wifi uitzetten: modems
10/08/18Netkaart hoogspanningslij
Artikelen
18/08/18Check if your mobile phon
18/08/18Eye Damage in the Microwa
17/08/18Monsanto moet 289 miljoen
17/08/18Ware WLAN ein medikament
16/08/18The full story on EMFs: R
11/08/185-10% Elektrosensiblen
Berichten Nederland
17/08/18De volksgezondheid is bli
15/08/18Huisarts ziet aantal stud
06/08/18’Buitengebied Hoogeveen
28/07/18OPEN BRIEF aan KPN en all
23/07/18Bijna 17.000 LTE-antennes
Berichten België
23/07/18Brusselse overheid tekent
16/06/18Scherpenheuvel-Zichem: Be
Berichten Internationaal
15/08/18USA: CDC Finds Brain, Liv
02/08/18Canada: First withdrawal
26/07/18ICNIRP’s public consult
17/07/18Frankrijk: PhoneGate scan
Ervaringen | Appellen/oproepen
29/07/18WMO aanvraag: ervaring
03/07/18Slimme meter ervaring
28/05/18Stralingsarme werkplek
Onderzoeken
18/08/18Exposure of Insects to Ra
04/08/18Occupational exposure to
29/07/18Oxidative stress in elect
Veel gestelde vragen
13/05/17Vakantie? Witte zo
10/07/16Zeven veel gestelde vrage
Juridische informatie
17/07/18De Omgevingswet en elektr
01/06/18Wetgeving hoogspanningsli
15/05/18Brit dad sues Nokia for u
Oproepen
13/08/18Oproep stralingsarme werk
23/07/18Oproep logeeradres Den Ha
29/06/18Tegenlicht wordt 30% geko
Folders
10/09/17Brochures, folders, websi
29/04/16USA: Meer dan 50 tips voo
Briefwisselingen | Archief: 2008, 2005
07/07/18E/mail naar alle raadsled
07/07/18E-mail naar de TV redacti
Illustraties
 Algemeen
 Fotoalbum zendmasten
 Wetenschappelijke illustraties
USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.    
Ga naar overzicht berichten in: Onderzoeken

USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.
dinsdag, 16 augustus 2011 - Dossier: Algemeen


Gerelateerd artikel: Berichten%20Internationaal/5991

Bron: British Journal of Cancer 9 August 2011; doi: 10.1038/bjc.2011.292

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

F P Costa 1, A C de Oliveira 1, R Meirelles 1, M C C Machado 1, T Zanesco 1, R Surjan 1,
M C Chammas 2, M de Souza Rocha 2,
D Morgan 3,
A Cantor 4,
J Zimmerman 5,
I Brezovich 6,
N Kuster 7,
A Barbault 8 and
B Pasche 5

1.
Department of Transplantation and Liver Surgery, Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo 05403-000, Brazil

2.
Department of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-000, Brazil

3.
Department of Radiology, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

4.
Biostatistics and Bioinformatics Shared Facility, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

5.
Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, 1802 6th Ave South, NP 2566, Birmingham, AL 35294-3300, USA

6.
Department of Radiation Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

7.
IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland

8.
Rue de Verdun 20, Colmar 68000, France

Correspondence:
Dr FP Costa, E-mail: fredericoperegocosta@gmail.com;
Dr B Pasche, E-mail: Boris.Pasche@ccc.uab.edu

Abstract
Background:

Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.

Methods:

A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival greater than or equal to6 months. Secondary efficacy end points were progression-free survival and overall survival.

Results:
Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7 months (95% CI 3.0–10.2). There were three partial and one near complete responses.

Conclusion:
Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.


Voor het originele abstract zie:
www.nature.com/bjc/journal/vaop/ncurrent/abs/bjc2011292a.html .


Ga terug naar het hoofdmenu
Afdrukken | Vragen | RSS | Disclaimer